Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2011-10-27 Interim / Quarterly Rep…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
111027 - Q3 Interim report_NL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interimverslag' (Interim Report) for UCB covering the first nine months of 2011. It contains substantive financial data, including revenue figures, EBITDA, and earnings per share, as well as detailed operational analysis of the company's drug portfolio and R&D pipeline. It is not merely an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). 9M 2011
2011-10-27 Dutch
111013 - shares acquisition_ENG.pdf
Transaction in Own Shares Classification · 99% confidence The document explicitly details the 'Acquisition of own shares in the framework of employees' long-term incentive plans' and provides a table showing the number of shares acquired, the price, and the date. This activity directly corresponds to the company buying back or transacting its own shares, which aligns perfectly with the definition of 'Transaction in Own Shares' (POS). The document is a formal announcement (indicated by 'regulated information' and the structure of a press release) detailing these specific transactions, not a general regulatory filing (RNS) or a report announcement (RPA).
2011-10-13 English
1110013 - shares acquisition_FR.pdf
Transaction in Own Shares Classification · 99% confidence The document text is titled "Acquisition d'actions propres dans le cadre de rémunérations variables à long terme du personnel" (Acquisition of own shares under long-term variable remuneration for personnel). It explicitly details the purchase of 16,500 UCB shares on specific dates and prices, stating these actions were delivered to employees exercising stock options. This activity directly corresponds to the company buying back or dealing in its own shares for employee compensation plans. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific corporate action related to share capital management.
2011-10-13 French
111013 - shares acquisition_NL.pdf
Transaction in Own Shares Classification · 99% confidence The document is titled 'Aankoop van eigen aandelen in het kader van langetermijnincentives toegekend aan het personeel' (Purchase of own shares in the context of long-term incentives granted to personnel). It explicitly details the purchase of UCB shares on the stock exchange and states that these shares were delivered to personnel who exercised their stock options. This activity directly relates to the company buying back or issuing shares, specifically in the context of employee compensation/incentives. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase/issuance. The document length (4399 chars) is substantial enough to be the primary filing, not just an announcement of a filing (RPA/RNS).
2011-10-13 Dutch
UCB credit facility renewed with improved terms
Capital/Financing Update Classification · 99% confidence The document is a press release dated October 10, 2011, announcing the successful amendment and restatement of UCB's EUR 1.0 billion revolving credit facility, detailing improved terms like maturity extension and removal of financial covenants. This clearly relates to the company's financing activities and capital structure. Based on the definitions, this fits best under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2011-10-10 English
UCB : Renouvellement et amélioration des termes de la facilité de crédit
Capital/Financing Update Classification · 99% confidence The document is a press release dated October 10, 2011, titled "UCB : Renouvellement et amélioration des termes de la facilité de crédit" (Renewal and improvement of the terms of the credit facility). It details the successful renegotiation and extension of a EUR 1 billion revolving credit facility, including reduced margins and removal of financial commitments. This content directly relates to the company's financing activities and capital structure management. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an earnings release (ER), an interim report (IR), or a full annual report (10-K).
2011-10-10 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.